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Abstract
Purpose: To describe the risk of early‐ and late‐onset preeclampsia across pregnancies
exposed to antidepressants and to evaluate the impact of timing and length of gestational expo-
sure to antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), on
preeclampsia.
Methods: The Norwegian Mother and Child Cohort, a prospective population‐based study,
and the Medical Birth Registry of Norway provided information on antidepressant exposure,
depression, and anxiety symptoms in pregnancy, preeclampsia diagnoses, and important covari-
ates. Within a pregnancy cohort of depressed women, we compared the risk of late‐onset pre-
eclampsia between SSRI‐exposed and nonmedicated pregnancies using marginal structural
models (weighted) and modified Poisson regression models.
Results: Of the 5887 pregnancies included, 11.1% were exposed at any time before week 34
to SSRIs, 1.3% to serotonin‐norepinephrine reuptake inhibitors, 0.4% to tricyclic antidepressants,
and 0.5% to other antidepressants. The risks of early‐ and late‐onset preeclampsia by exposure
status in pregnancy were 0.3% and 3.6% (nonmedicated), 0.4% and 3.7% (SSRIs), 1.5% and
4.1% (serotonin‐norepinephrine reuptake inhibitors), and 7.1% and 10.0% (tricyclic antidepres-
sants). Compared with nonmedicated pregnancies, SSRI‐exposed in mid and late gestation had
adjusted relative risks for late‐onset mild preeclampsia of 0.76 (95% confidence interval,
0.38‐1.53) and 1.56 (0.71‐3.44) (weighted models), respectively. There was no association
between SSRI exposure in pregnancy and severe late‐onset preeclampsia.
Conclusions: We have provided evidence that SSRI use in early and midpregnancy does not
substantially increase the risk of late‐onset preeclampsia.
KEYWORDS
antidepressant, MoBa, pharmacoepidemiology, preeclampsia, pregnancy, SSRI, The Norwegian
Mother and Child Cohort Study
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1 | INTRODUCTION
During pregnancy, up to 20% of women have depressive symptoms,1
and 1% to 8% are treated with antidepressants, mainly selective
serotonin reuptake inhibitors (SSRIs).2,3 It has been suggested that
SSRIs may increase the risk of preeclampsia.4-7 Preeclampsia is a major
complication affecting 3% to 5% of all pregnancies and is cause of
maternal‐infant morbidity and mortality.8
Toh et al4 were the first to show an association between use of
SSRI beyond the first trimester and increased risk of preeclampsia
compared to no use (4.9‐fold magnitude). While some studies
replicated this association, albeit with smaller effect sizes (16‐60%
increased risk),5,6,9,10 other studies did not.7,11 Three of these7,9,11
found that women prenatally exposed to serotonin‐norepinephrine
reuptake inhibitors (SNRIs) or tricyclic antidepressants (TCAs) had an
elevated risk of preeclampsia.
Antidepressants and maternal mood disorders may via different
pathways trigger pathogenic vascular processes leading to preeclamp-
sia,12,13 and this poses challenges in disentangling the effect of pharma-
cotherapy from that of the underlying depression. Although some prior
studies have compared the risk of preeclampsia in depressed women
treated versus untreated with antidepressants and adjusted for proxy
measures of depression severity (eg, number of outpatient and inpatient
depression diagnoses or other antidepressant [OAD] indications),5,9-11
none of them could directly measure depression severity and account
for its possible fluctuation at 2 time points in pregnancy.
In a pregnancy cohort of depressed women, we aimed to (1)
describe the risk of early‐ and late‐onset preeclampsia across women
prenatally exposed to various antidepressants and (2) closely examine
the association between timing and length of gestational exposure to
SSRIs and late‐onset preeclampsia, accounting for time‐varying
exposure and severity of depressive and anxiety symptoms during
pregnancy.
2 | METHODS
This study is based onThe Norwegian Mother and Child Cohort Study
(MoBa) linked to the Medical Birth Registry of Norway (MBRN) via
women0s personal identification number. The MoBa is a prospective
population‐based pregnancy cohort study conducted by the
Norwegian Institute of Public Health.14 Participants were recruited
from all over Norway in 1999 to 2008 through a postal invitation in
connection with a routine ultrasound at gestational weeks (GWs) 17
and 18. Data were gathered prospectively from 2 self‐completed
questionnaires at GWs 17 (Q1) and 30 (Q3). Women consented to
participation in 41% of the pregnancies, and among these, the
response rate was 95% for Q1 and 92% for Q3.15 The cohort now
includes 114 500 children, 95 200 mothers, and 75 200 fathers. The
current study is based on version 8 of the quality‐assured data files
released for research including women who delivered between 1999
and 2009. The establishment and data collection in MoBa has obtained
a license from the Norwegian Data Inspectorate and approval fromThe
Regional Committee for Medical Research Ethics. All participants gave
their written informed consent prior to participation.
The MBRN is based on compulsory notification of all live births,
stillbirths, and induced abortions after GW 12 (after week 16 up to
2002) since 1967.16 This study included pregnancies within women
with a medicated depression in the 6 months prior to pregnancy
and/or with depression during pregnancy, as self‐reported in Q1
and/or Q3. Both questionnaires included a list of previous and/or con-
current illnesses, including depression, and were completed at a mean
GW of 17.5 (SD, 2.8) and 30.7 (SD, 1.7). The exclusion criteria and
flowchart to achieve the final analysis cohort are outlined in Figure 1.
2.1 | Depression and anxiety symptoms in pregnancy
The short versions of The Hopkins Symptom Checklist–25 (SCL‐25), ie,
the 5‐ (SCL‐5) and 8‐item (SCL‐8) scales, were used to measure sever-
ity of depressive and anxiety symptoms at GWs 17 and 30, respec-
tively.15,16 Both scales measure symptoms in the last 2 weeks prior
to completion and are highly correlated to the SCL‐25,17 a reliable
screening instrument for depression as defined by the 10th revision
of the International Statistical Classification of Diseases and Related
Health Problems.17 For each SCL item, a score from 1 to 4 can be
assigned. The sum score was calculated and divided by the number
of items in each instrument.
To reflect the temporality of data collection in MoBa, as well as
the time points in gestation when on average Q1 and Q3 were com-
pleted, and the SCL measurement validity time span, we considered
3 time points: T0 (GWs 0‐16), T1 (GWs 17‐28), and T2 (GWs 29‐34)
(Figure 2).
2.2 | Exposure
The Q1 and Q3 provided information about antidepressant exposure.
Women reported the name of the medication taken along with timing
of use (6 months before pregnancy and during pregnancy by 4‐week
intervals). Drug classification was based on the Anatomical Therapeu-
tic Chemical (ATC) Classification System.18 Exposure to antidepres-
sants was defined as exposure to a drug belonging to the ATC group
KEY POINTS
• This study extends the literature by considering 2
measures of depressive and anxiety symptom severity
in pregnancy.
• SSRI exposure in early and midpregnancy did not
substantially increase the risk of late‐onset
preeclampsia.
• Our study could rule out a 2‐fold increased risk of late‐
onset preeclampsia following SSRI exposure in late
pregnancy, although we were unable to confirm or
refute whether a smaller increased risk exists.
• The crude risk of early‐ and late‐onset preeclampsia was
higher among SNRI‐ and TCA‐exposed pregnancies than
among depressed nonexposed.
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N06A, subdivided into SSRIs (ATC: N06AB), SNRIs (venlafaxine and
duloxetine), TCAs (ATC: N06AA), and OADs (mianserin, nefazodone,
mirtazapine, bupropion, and reboxetine). Women on antidepressant
polytherapy, ie, exposed to multiple antidepressant groups in preg-
nancy, were excluded (Figure 1).
The primary exposure windows were early (T0), mid (T1), and late
(T2) pregnancy, with the addition of any time in pregnancy (T0‐T2).
The rationale behind this exposure definition is described in
Appendix 1.
Length of antidepressant exposure was defined according to how
many 4‐week intervals were checked in the questionnaires: 0, 1, 2 to 4,
and 5 to 8 intervals. Women were classified as exposed if they
reported use of SSRIs, SNRIs, TCAs, or OADs during these periods.
When more than one medication was reported for the same indication,
we assumed that all medications were taken at the intervals checked.
Based on previous studies,4,7,9 we also defined, among the pre‐
pregnancy SSRI exposed, continuers beyond the first trimester and
discontinuers within the same period. We expanded this approach to
FIGURE 1 Flowchart to achieve the final
analysis cohort*. MBRN, Medical Birth
Registry of Norway; MoBa, The Norwegian
Mother and Child Cohort Study; Q1, MoBa
questionnaire 1; Q3, MoBa questionnaire 3.
*Conditions may overlap. aWomen with
multifetal gestation have one pregnancy
record per fetus; a single pregnancy record
was retained in the final eligible cohort.
bIncludes both induced and spontaneous
abortions. cWomen who did not report any
medication for treatment of depression but
checked the boxes related to timing of use of
medication either before or during pregnancy.
dWomen on therapy with antidepressants
belonging to different antidepressant groups
(eg, selective serotonin reuptake inhibitor and
tricyclic antidepressant). ePreeclampsia with
onset after gestational week 34, also including
eclampsia and hemolysis, elevated liver
enzymes, and low platelet count syndrome
postdelivery. fPreeclampsia with onset
between gestational weeks 20 and 34
FIGURE 2 Directed acyclic graph for the
outcome late‐onset preeclampsia. GW,
gestational week. Z is a vector of baseline
covariates; EXP_0, EXP_1, and EXP_2
represent antidepressant exposure,
specifically selective serotonin reuptake
inhibitors in GW 0‐16, 17‐28, and 29‐34; L_1
is a vector of time‐varying confounders,
including comedication with analgesics during
weeks 0‐16 and depressive/anxiety symptoms
measured at GW 17; L_2 is a vector of time‐
varying confounders, including comedication
with analgesics during weeks 17‐28 and
depressive/anxiety symptoms measured at
GW 30. Y is the outcome measure, late‐onset
preeclampsia
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later gestation, ie, continuers in first half of third trimester versus
discontinuers among midpregnancy SSRI users.
2.3 | Outcome
The main outcome variable was late‐onset preeclampsia (any severity,
mild, and severe), ie, preeclampsia developing after GW 34 as regis-
tered in the MBRN. Information provided in the registry is based on
forms completed by midwives/obstetricians at delivery and during pre-
natal checkups. The main outcome variable included any diagnosis of
late‐onset preeclampsia (mild, severe, or unspecified); hemolysis, ele-
vated liver enzymes, and low platelet count; and eclampsia. Severe
preeclampsia included the following diagnoses: severe preeclampsia;
hemolysis, elevated liver enzymes, and low platelet count syndrome;
or eclampsia. Mild preeclampsia diagnosis was used when given alone.
Early‐onset preeclampsia was included as secondary outcome, ie,
developing between GWs 20 and 34. Late‐ and early‐onset preeclamp-
sia were treated as mutually exclusive outcomes since they are gener-
ally regarded as subtypes of preeclampsia.19,20 Details about the
diagnostic criteria for preeclampsia in Norway21 are outlined in
Appendix 1. The validity of preeclampsia registration in the MBRN
for MoBa participants has been assessed against antenatal records/
hospital discharge codes, yielding a positive predictive value of 84%;
upon generalization to the whole eligible MoBa population, the sensi-
tivity was 43% and the specificity 99%.22
2.4 | Covariates
Relevant confounding factors were identified with the aid of directed
acyclic graphs.23 Maternal age, parity, education, income, body mass
index at conception, smoking status during pregnancy until week 30,
depressive and anxiety symptoms in pregnancy, and comedication with
analgesics (ie, opioids and nonsteroidal anti‐inflammatory drugs) or
other psychotropics (ie, antipsychotics, anxiolytics, hypnotics, and sed-
atives) in pregnancy were all ascertained from Q1 and Q3. The MoBa
Q1 also captured information about lifetime event of major depression
via utilization of the “The Life Time History of Major Depression”
instrument,24 comprising 6 items, which closely correspond to the
DSM‐III criteria for lifetime major depression. Obstetric risk factors
for preeclampsia were ascertained from the MBRN (ie, multiple gesta-
tion, history of preeclampsia, chronic hypertension, gestational diabe-
tes, and infertility treatment) and Q1 (ie, maternal blood pressure at
the first antenatal visit).
2.5 | Statistical analysis
All statistical analyses were performed by using STATA version 14.
Details about the study power in relation to SSRIs/late‐onset pre-
eclampsia are given in Appendix 1. Our study was underpowered for
the SNRI‐, TCA‐, and OAD‐exposed group, as well as for the outcome
early‐onset preeclampsia, for which only descriptive statistics are
presented.
To estimate the relative risks (RRs) of late‐onset preeclampsia
(overall and by severity) along with their corresponding 95% confi-
dence interval (CI) in relation to SSRI exposure, 2 sets of analyses were
performed. First, we used modified Poisson regression models within
the generalized linear model framework (unweighted models). A
robust variance estimator was applied to account for women0s partic-
ipation with more than one pregnancy in MoBa. We computed crude
and adjusted RRs (aRRs) with 95% CI for the exposure windows;
adjustment was done for a sufficient set of confounders (ie, maternal
age, parity, body mass index, education, income, smoking status and
weight gain, comedication with analgesics and other psychotropics,
depressive symptoms as average of the standardized z‐scores at each
time point, and lifetime event of major depression).
In the second set (weighted models), we fit marginal structural
models to account for time‐varying SSRI exposure and time‐varying
confounders (depressive and anxiety symptoms in pregnancy and
comedication with analgesics) (Figure 2).25 We estimated the probabil-
ity of SSRI treatment using a pooled logistic regression in which the
outcome was current SSRI treatment. The covariates were maternal
baseline factors, time‐varying confounders at T1 and T2, time‐fixed
confounders, and SSRI history treatment (T0 exposure) (Appendix 2).
We derived stabilized inverse probability of treatment weights (IPTW)
for each pregnancy at each time point. We then fit a modified Poisson
regression model with robust standard errors applying the IPTW. To
avoid violation of the positivity assumption, we only included pregnan-
cies of depressed women in the analysis. Data are presented as crude
and aRR with 95% CI in both weighted and unweighted models.
Missing values on confounders ranged from 1% to 15%. Under the
assumption that data were missing at random, we imputed missing
values via multiple imputation (20 replications). Imputed data were
used in both analysis sets. Details about missing data are provided in
Appendix 1.
2.6 | Sensitivity and subanalyses
A number of sensitivity and subanalyses were undertaken. We consid-
ered in the main analyses major obstetric risk factors for preeclampsia
and baseline maternal blood pressure by adjustment and restriction.
Since parity is a major risk factor for preeclampsia, we run subanalyses
among nulliparous women and explored any effect modification by
parity. We also repeated the analysis restricted to the first pregnancy
recorded in case of multiple participations in MoBa to limit selection
bias by healthier maternal status. For comparison purposes with prior
research,4,5,9-11 we explored in the unweighted models the effect of
early SSRI exposure on preeclampsia as an aggregated outcome mea-
sure and compared SSRI‐exposed pregnancies in the specific time win-
dows to the depressed, never medicated counterpart. We examined
the sensitivity of the findings in the weighted models by applying dif-
ferent model specifications including obstetric risk factors for pre-
eclampsia and baseline maternal blood pressure or excluding
covariates thought to lead to more extreme stabilized weights (cf
Appendix 2). To explore the bias‐precision trade‐off, we progressively
truncated the IPTW at 1st/99th and 5th/95th percentile.25 We con-
ducted complete‐case analyses and considered in the analysis only
SCL imputed values whenever more than a half of the items were com-
pleted with exclusion of pregnancies with missing information on the
other important covariates. We conducted probabilistic sensitivity
analyses to correct for exposure and outcome misclassification,
unmeasured confounding and random error simultaneously using bias
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parameters (10 000 simulations) stemming from existing studies.22,26,27
The latter validation study27 showed a specificity of 99.9% and a sensi-
tivity of 81.7% for SSRI use in mid/late pregnancy as reported in MoBa.
To address unmeasured confounding by nutrition (ie, adherence to the
Nordic diet, consisting of healthy foods native to a Nordic climate), we
used prevalence estimates for high diet adherence ranging from 0.30 to
0.5028 and assumed that high adherence to the Nordic diet was half as
prevalent in SSRI users than in nonusers. We allowed the association
between high diet adherence and late‐onset preeclampsia to vary
between 0.50 and 0.80.28
3 | RESULTS
The final analysis cohort included 5887 pregnancies ending with a live‐
born (99.8%) or stillborn (0.2%, >GW 34) infant (Figure 1). Lost to fol-
low‐up (ie, Q3 not completed) occurred more often within younger,
more disadvantaged women with more severe early gestation depres-
sive symptoms compared to women remaining in the study (ie, both
Q1 and Q3 completed). Lost to follow‐up pregnancies presented
higher rates of early‐ but not of late‐onset preeclampsia.
Baseline sociodemographic, lifestyle, and health characteristics of
the 5887 pregnancies in women with depression by antidepressant
treatment status are shown inTable 1. The SSRI monotherapy (hereaf-
ter, SSRI) was the most common antidepressant exposure at any time
in pregnancy before GW 34 (654/5887; 11.1%), with rates of use rang-
ing from 10.1% in early to 4.1% and 3.4% in mid and late pregnancy,
respectively. Few pregnancies were exposed to monotherapy with
SNRIs (1.3%), TCAs (0.4%), or OADs (0.5%) at any time before GW 34
(Table 1).
Early‐ and late‐onset preeclampsia complicated 19 (0.3%) and 213
(3.6%) of the pregnancies. The incidence of late‐onset mild, severe, and
unspecified preeclampsia was 2.4%, 1.0%, and 0.2%, respectively. The
risk of late‐onset preeclampsia by exposure status at any time before
GW 34 is outlined in Figure 3A, whereas Figure 3B depicts the risk
of early‐preeclampsia according to antidepressant exposure in early
pregnancy.
Five thousand seven hundred forty‐five pregnancies from 5550
women were analyzed in relation to the effect of SSRIs on late‐
onset preeclampsia (hereafter, preeclampsia). There was no associa-
tion between SSRI exposure in early, mid, late, or at any time in
pregnancy and preeclampsia of any severity in the unweighted
models (Table 2). Adjustment for the necessary set of confounders
did not substantially affect the crude estimates, with depressive
and anxiety symptoms being the covariates having the largest
impact. There was no effect modification by parity. In the weighted
model, the effect estimate for SSRI exposure in midpregnancy (aRR,
0.66; CI, 0.33‐1.28) was lower than the one observed in the
unweighted model, while larger for the late pregnancy window
(aRR, 1.34; CI, 0.61‐2.93); however, the CIs were wide and included
the null. Table 2 also outlines the effect estimates for mild pre-
eclampsia according to timing of SSRI exposure.
Table 3 summarizes unweighted RR for preeclampsia (any sever-
ity) according to length of SSRI exposure and continuation/discontinu-
ation beyond first trimester. No severity‐specific analyses were
conducted because of low statistical power. Of the 240 pregnancies
exposed to SSRIs in midpregnancy, 194 continued the treatment in
late pregnancy and 8 of these (4.1%) developed preeclampsia, com-
pared to none among discontinuers.
3.1 | Sensitivity and subanalyses
The results of the unweighted (not shown) and weighted (Appendix 2)
main models accounting for major obstetric risk factors for preeclamp-
sia and maternal baseline blood pressure did not materially change our
main findings. Restriction to nulliparous women, aggregation of early/
late‐onset preeclampsia in a unique outcome (Appendices 3 and 4),
comparison of SSRI‐exposed pregnancies in the specific time windows
to the depressed, never medicated counterpart in the unweighted
analysis, and alternative model specifications in the weighted
(Appendix 2) did not produce substantially different results. The pro-
gressive IPTW truncation yielded an SSRI late exposure estimate with
larger standard error, and the stabilized weight did not achieve better
precision.
Appendices 1, 5, and 6 outline the distribution of key variables in
relation to missingness and results of the complete case analyses.
The complete case analysis estimates were higher than those found
in the imputed data, particularly for SSRI early exposure. The
unweighted and weighted results of the complete case analyses
expanded to pregnancies with only SCL imputed values did not sub-
stantially deviate from the main findings (Appendix 7). Results of prob-
abilistic bias analyses are summarized in Appendices 8 and 9 and
supported our main findings.
4 | DISCUSSION
This study adds to the conflicting literature on the effect of SSRIs in
pregnancy on preeclampsia and has the unique advantage of being
able to account for severity of anxiety and depressive symptoms
throughout gestation. We found no evidence that exposure to SSRIs
in early or midpregnancy increases the risk of late‐onset preeclampsia.
Our findings on SSRI midpregnancy exposure are partly in line with
one prior study11 but also in contrast with 5 other studies.4-6,9,10 These
discrepancies may be caused by several factors: different definitions of
timing of exposure and outcome, lack of information on depression
severity during gestation in all prior research, and cohort inclusion con-
ditions (ie, live birth only versus live birth and stillbirth pregnancies),
which may have introduced collider stratification bias. Missing data
handling may have also produced divergent results. Our unweighted
complete case analysis produced larger point estimates, which were
partly in line with some prior studies.5,9,10 The missing data mechanism
in our study seemed to be linked to maternal age and to the extent of
completion of the SCL items, and as supported by our sensitivity
analyses, a complete case analysis approach could have yielded biased
estimates.29
When accounting for time‐varying severity of maternal depression
and anxiety symptoms, we found that compared to nonexposed, the
risk of late‐onset mild preeclampsia was lower among midpregnancy
SSRI‐exposed (24% decreased risk) but higher (56% increased risk)
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TABLE 1 Sociodemographic, lifestyle, and health characteristics of the sample by antidepressant use status during pregnancy before gestational
week 34 (n = 5887)
Depression,
Nonmedicated
Depression, SSRI
Monotherapy
Depression, SNRI
Monotherapy
Depression, TCA
Monotherapy
Depression, OAD
Monotherapy
n = 5106 n = 654 n = 75 n = 21 n = 31
Maternal age, y; mean ± SD 29.6 ± 5.1 30.0 ± 5.0 29.2 ± 5.6 31.0 ± 5.5 30.9 ± 4.3
Multiple gestation; no., %
No 5030 (98.5) 637 (97.4) 73 (97.3) 21 (100.0) 30 (96.8)
Yes 76 (1.5) 17 (2.6) 2 (2.7) — 1 (3.2)
Gestational age at delivery, wk; mean ± SD 39.4 ± 1.70 39.1 ± 1.81 39.2 ± 1.98 38.6 ± 1.53 39.1 ± 1.88
Parity; no., %
0 2410 (47.2) 357 (54.6) 38 (50.7) 10 (47.6) 12 (38.7)
≥1 2696 (52.8) 297 (45.4) 37 (49.3) 11 (52.4) 19 (61.3)
Marital status; no., %
Married/cohabiting 4663 (91.3) 566 (86.5) 62 (82.7) 20 (95.2) 28 (90.3)
Other 399 (7.8) 84 (12.8) 11 (14.7) 1 (4.8) 3 (9.7)
Educational level; no., %
University/college 2428 (47.6) 311 (47.6) 29 (38.7) 7 (33.3) 15 (48.4)
Lower than university/college 2326 (45.6) 301 (46.0) 43 (57.3) 14 (66.7) 16 (51.6)
Woman0s gross yearly income, NOK; no., %
No income 204 (4.0) 29 (4.4) 1 (1.3) 1 (4.8) 1 (3.2)
<199 999 1858 (36.4) 277 (42.4) 31 (41.3) 9 (42.9) 16 (51.6)
200‐399 999 2470 (48.4) 286 (43.7) 33 (44.0) 10 (47.6) 11 (35.5)
>400 000 402 (7.9) 43 (6.6) 7 (9.3) 1 (4.8) 1 (3.2)
BMI at conception; mean ± SD 24.3 ± 4.6 24.5 ± 4.9 24.5 ± 5.0 25.6 ± 4.5 22.6 ± 3.7
Weight gain, kg, until GW 30; mean ± SD 9.8 ± 5.4 9.5 ± 5.4 10.9 ± 6.0 10.0 ± 4.8 9.7 ± 6.6
Smoking status at GW 30; no., %
No 3643 (71.4) 439 (67.1) 42 (56.0) 15 (71.4) 13 (41.9)
Yes 728 (14.3) 111 (17.0) 22 (29.3) 3 (14.3) 10 (32.3)
Stopped in pregnancy 683 (13.4) 100 (15.3) 9 (12.0) 3 (14.3) 8 (25.8)
Infertility treatment; no., %
No 4831 (94.6) 623 (95.3) 72 (96.0) 20 (95.2) 28 (90.3)
Yes 275 (5.4) 31 (4.7) 3 (4.0) 1 (4.8) 3 (9.7)
Chronic hypertension and use of antihypertensive
before conception; no., %
No 5098 (99.8) 653 (99.9) 75 (100.0) 21 (100.0) 31 (100.0)
Yes 8 (0.2) 1 (0.1) — — —
Systolic blood pressure, mm Hga; mean ± SD 113.1 ± 12.5 111.7 ± 13.1 107.7 ± 9.8 114.8 ± 14.4 110.0 ± 15.0
Diastolic blood pressure, mm Hga; mean ± SD 68.1 ± 9.6 67.3 ± 9.7 66.0 ± 8.2 69.4 ± 9.0 66.8 ± 9.7
Preexisting diabetes; no., %
No 5181 (99.4) 650 (99.4) 75 (100.0) 21 (100.0) 31 (100.0)
Yes 34 (0.7) 4 (0.6) — — —
Preeclampsia history; no., %
No 4910 (96.2) 627 (95.9) 71 (94.7) 21 (100.0) 29 (93.6)
Yes 196 (3.8) 27 (4.1) 4 (5.3) — 2 (6.5)
History of spontaneous abortion(s)b; no., %
No 3480 (68.2) 466 (71.3) 53 (70.7) 13 (61.9) 18 (58.1)
Yes 1000 (19.6) 121 (18.5) 12 (16.0) 6 (28.6) 12 (38.7)
Lifetime major depressionc; no., %
No 1328 (26.0) 46 (7.0) 7 (9.3) 2 (9.5) 2 (6.4)
Yes 3491 (68.4) 582 (89.0) 66 (88.0) 19 (90.5) 29 (93.6)
Depressive symptoms at GW 17; z‐score ± SD −0.03 ± 0.98 0.18 ± 1.11 0.37 ± 1.15 0.14 ± 0.87 0.39 ± 1.08
Depressive symptoms at GW 30; z‐score ± SD −0.02 ± 0.97 0.10 ± 1.13 0.43 ± 1.39 0.31 ± 1.08 0.44 ± 1.31
(Continues)
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among SSRI‐exposed in late pregnancy. Although the estimate CIs
were wide and crossed the null effect, these divergent estimates may
suggest the importance of timing of SSRI exposure and/or of time‐
specific interplay of biological mechanisms in relation to preeclampsia.
Depression and anxiety may plausibly increase the risk of preeclampsia
via an altered excretion of vasoactive hormones or other neuroendo-
crine transmitters.30,31 Treatment with SSRIs seems to normalize the
dysfunction of the hypothalamic‐pituitary‐adrenal axis and could
thereby reduce the risk of preeclampsia posed by depression through
this mechanism.32 It is possible that our findings on late pregnancy
TABLE 1 (Continued)
Depression,
Nonmedicated
Depression, SSRI
Monotherapy
Depression, SNRI
Monotherapy
Depression, TCA
Monotherapy
Depression, OAD
Monotherapy
n = 5106 n = 654 n = 75 n = 21 n = 31
Comedication use in pregnancy; no., %
Other psychotropic drugsd 142 (2.8) 81 (12.4) 10 (13.3) 5 (23.8) 8 (25.8)
NSAIDs and/or opioid analgesics 450 (8.8) 85 (13.0) 11 (14.7) 3 (14.3) 6 (19.4)
Abbreviations: BMI, body mass index; GW, gestational week; NOK, Norwegian Krone (1 NOK=0.13 USD); NSAID, nonsteroidal anti‐inflammatory drugs;
OADs, other antidepressants; SNRIs, serotonin‐norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCA, tricyclic
antidepressants.
Numbers may not add up to total due to missing values, ranging from 1% to 3% for smoking, BMI, and socioeconomic status, to 5% to 7% for educational
level, lifetime history of major depression and depressive, and anxiety symptoms in GW 17, 8% to 10% for depressive and anxiety symptoms in GW 30 and
weight gain, and 14% for baseline blood pressure values.
aSelf‐reported systolic and diastolic blood pressure as measured at first antenatal visit.
bDefined as history of spontaneous abortion(s) before GW 12.
cDefined as Kendlers lifetime major depression scale score of 3 or more of 6 depressive symptoms of duration of more than 2 weeks.
dOther psychotropic drugs include all medications under the Anatomical Therapeutic Chemical code N05, ie, antipsychotics, anxiolytics, hypnotics, and
sedatives.
FIGURE 3 Risk of A, late‐onset (ie, later than
week 34) and B, early‐onset (ie, weeks 20‐34)
preeclampsia by antidepressant exposure
status. SSRI, selective serotonin reuptake
inhibitor; SNRI, serotonin‐norepinephrine
reuptake inhibitor; TCA, tricyclic
antidepressant; OAD, other antidepressant.
Antidepressant exposure in gestational weeks
0‐34 (within A) and antidepressant exposure
in gestational weeks 0‐16 (within B). The
Other antidepressant (OAD) exposure group
not presented in A, since there were no cases
of late‐onset preeclampsia
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TABLE 2 Risk of late‐onset preeclampsia—overall and by severity—according to timing of SSRI exposure in pregnancy (n = 5745)
Depressed Cohort Total
N (%) with
Outcome Crude RR (95% CI)
Unweighted Adjusted
RRa (95% CI)
Weighted Adjusted
RRb (95% CI)
Preeclampsia, any severity
Nonmedicated, GWs 0‐16 5154 186 (3.6) Reference Reference
SSRI, GWs 0‐16 591 22 (3.7) 1.03 (0.67‐1.59) 0.96 (0.63‐1.46) —
Nonmedicated, GWs 17‐28 5505 200 (3.6) Reference Reference Reference
SSRI, GWs 17‐28 240 8 (3.3) 0.92 (0.46‐1.84) 0.92 (0.48‐1.79) 0.66 (0.33‐1.28)
Nonmedicated, GWs 29‐34 5547 200 (3.6) Reference Reference Reference
SSRIs, GWs 29‐34 198 8 (4.0) 1.12 (0.56‐2.24) 1.08 (0.57‐2.07) 1.34 (0.61‐2.93)
Nonmedicated, GWs 0‐34 5093 184 (3.6) Reference Reference
SSRIs, GWs 0‐34 652 24 (3.7) 1.02 (0.67‐1.55) 0.96 (0.64‐1.45) —
Preeclampsia, mild
Nonmedicated, GWs 0‐16 5092 124 (2.4) Reference Reference
SSRI, GWs 0‐16 585 16 (2.7) 1.12 (0.67‐1.88) 1.05 (0.63‐1.75) —
Nonmedicated, GWs 17‐28 5438 133 (2.5) Reference Reference Reference
SSRI, GWs 17‐28 239 7 (2.9) 1.20 (0.57‐2.53) 1.22 (0.59‐2.54) 0.76 (0.38‐1.53)
Nonmedicated, GWs 29‐34 5480 133 (2.4) Reference Reference Reference
SSRI, GWs 29‐34 197 7 (3.6) 1.46 (0.69‐3.09) 1.49 (0.73‐3.04) 1.56 (0.71‐3.44)
Nonmedicated, GWs 0‐34 5031 122 (2.4) Reference Reference
SSRI, GWs 0‐34 646 18 (2.8) 1.15 (0.71‐1.87) 1.10 (0.67‐1.80) —
Preeclampsia, severe
Nonmedicated, GWs 0‐34 4959 50 (1.0) Reference Reference
SSRI, GWs 0‐34 633 5 (0.8) 0.78 (0.31‐1.96) 0.72 (0.31‐1.68) —
Abbreviations: CI, confidence interval; GW, gestational week; RR, relative risk; SSRI, selective serotonin reuptake inhibitors.
Numbers of severe and mild late‐onset preeclampsia may not add up to total due to cases of unspecified late‐onset preeclampsia. Data are not shown
because of low number of cases. Severe late‐onset preeclampsia could only be explored in relation to the exposure window GWs 0‐34 because of low sta-
tistical power.
aAdjusted for maternal age, body mass index at conception, woman0s socioeconomic status, educational level, parity, smoking status in pregnancy, weight
gain, comedication with analgesics or other psychotropics, lifetime history of major depression, and average z‐score of depressive and anxiety symptoms
at 2 time points in pregnancy.
bMarginal structural model weighted with stabilized inverse probability of treatment weighting constructed at each time point using baseline covariates,
time‐varying and time‐fixed confounding factors, and SSRI history treatment.
TABLE 3 Risk of late‐onset preeclampsia (any severity) according to length of SSRI exposure in pregnancy and continuation/discontinuation in
early pregnancy (n = 5745)
Depressed Cohort Total N (%) with Outcome Crude RR (95% CI) Unweighted Adjusted RRa (95% CI)
Preeclampsia, any severity
Nonmedicated, ever 5127 186 (3.6) Reference Reference
SSRI in 1 interval 220 6 (2.7) 0.75 (0.34‐1.68) 0.70 (0.32‐1.55)
SSRI in 2‐4 intervals 203 8 (3.9) 1.09 (0.54‐2.17) 0.96 (0.48‐1.91)
SSRI in 5‐8 intervals 195 8 (4.1) 1.13 (0.57‐2.26) 1.16 (0.60‐2.24)
SSRI in 1 interval 220 6 (2.7) Reference Reference
SSRI in 2‐4 intervals 203 8 (3.9) 1.44 (0.51‐4.10) 1.27 (0.42‐3.82)
SSRI in 5‐8 intervals 195 8 (4.1) 1.50 (0.53‐4.26) 1.47 (0.56‐3.90)
SSRI discontinuersb 246 7 (2.9) Reference Reference
SSRI continuersc 208 11 (5.3) 1.86 (0.73‐4.71) 1.63 (0.66‐4.03)
Abbreviations: CI, confidence interval; RR, relative risk; SSRI, selective serotonin reuptake inhibitor.
aAdjusted for maternal age, body mass index at conception, woman0s socioeconomic status, educational level, parity, smoking status in pregnancy, weight
gain, comedication with analgesics or other psychotropics, lifetime history of major depression, and average z‐score of depressive and anxiety symptoms
at 2 time points in pregnancy.
bDefined as SSRI exposed pregnancies before pregnancy, but SSRI treatment discontinued within the first trimester (ie, before gestational week 13).
cDefined as SSRI exposed pregnancies before pregnancy and SSRI treatment continued in and beyond the first trimester.
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SSRI exposure may be ascribed to residual confounding by depression
severity or stress at the very end of gestation.
There are however biological mechanisms supporting a role of
SSRIs in preeclampsia, which may be relevant during the maternal
systemic response to preeclampsia. The SSRIs elicit increased levels
of serotonin,12 which in turn enhance vasoconstriction on the
umbilical‐placental vessels, and they also inhibit synthesis of nitric
oxide, an important vasodilator.33,34 In late gestation pregnant sheep,
for instance, there was a transient reduction of uterine artery blood
flow following fluoxetine administration.35 Our point estimate by
length of SSRI exposure (5‐8 vs one 4‐week interval) was of similar
magnitude to that observed in a prior study,11 although the CIs were
wide and crossed the null effect. Palmsten et al11 also found no
association between cumulative SSRI dose and preeclampsia, which
raises the question of whether timing of exposure may be linked to
preeclampsia rather than cumulative dose; this could also be
supported by our findings on the extent of preeclampsia in relation
to SSRI continuation/discontinuation in the first half of the third
trimester. Since maternal susceptibility to vascular damage and
factors other than poor placentation are etiologically relevant for
late‐onset preeclampsia,36 our findings may provide, together with
prior research,37 some hints about the underlying mechanisms of this
elusive syndrome.
The elevated risk for preeclampsia observed among TCA‐exposed
pregnancies at any time before week 34 aligns with findings of 2 pre-
vious studies (10‐11%),9,11 while the one for SNRI exposure was not as
large (6‐9%). Because of their vasoconstrictive effects,12 SNRIs and
TCAs may plausibly be linked to preeclampsia, but the elevated risk
seen in relation to early preeclampsia would also indicate a potential
role of these medications on placentation. The small sample size how-
ever impeded us to conduct adjusted analyses and further explore
these potential associations.
4.1 | Strengths and limitations of the study
There are several strengths and limitations inherent this investigation
and the MoBa study. Data collection was conducted prospectively,
avoiding the risk of recall bias. Distinction of early‐ from late‐onset
preeclampsia reduced the risk of reverse causality. We could account
for several health‐related and maternal factors, including severity of
depressive and anxiety symptoms in pregnancy via a validated
instrument. Although this latter measurement cannot replace a clinical
interview and is not designed to measure perinatal mood specifically, it
provides a reliable measure of the severity of these psychiatric
conditions.17,38 We accounted for unmeasured confounding by diet
quality,28 conducted several sensitivity and subanalyses to explore
the robustness of our findings, and also explored the impact of missing
information on important covariates on our estimates. However,
residual confounding by depression severity or number of cigarette
smoked during gestation cannot be ruled out.
One limitation is that antenatal depression was self‐reported in
MoBa. However, our analysis cohort was about 5% of the initial data
source, which equals estimates of major depression in pregnancy
based on structural clinical interviews.1 Depressive and anxiety symp-
toms were not measured at baseline, but only at 2 time points in
pregnancy; however, information about lifetime history of major
depression was used in the generation of the stabilized weights. Expo-
sure and outcome misclassification could be an additional concern. Use
of antidepressants was self‐reported; however, the impact of SSRI mis-
classification has been explored and assessed as minimal for mid/late
pregnancy exposure.27 Yet the impact of misclassification of SSRI
exposure in terms of length and by the individual 4‐week intervals
has not been addressed. Information on dosage is not available in the
MoBa, and data about duration of exposure are not complete. The pos-
itive predictive value for a diagnosis registration of preeclampsia in the
MBRN was found to be 84%, and false negative cases seemed to have
mild forms of preeclampsia.22 The results of probabilistic bias analyses
did not materially change our main conclusions.
The MoBa study has a low response rate (41%), with a possible
self‐selection of the healthiest women.15 Its potential for bias has been
thoroughly explored by comparing the MoBa with the total Norwegian
birthing population,39 and although the prevalence estimates could not
necessarily be generalized, the measures of associations tested were
valid in the MoBa. We cannot, however, rule out that selection bias
and/or lost to follow‐up of more disadvantaged women may have
impacted the study results. Our sample size limited the statistical
power of the analysis on mid and late pregnancy SSRI exposure, and
impeded us to explore antidepressants other than SSRIs, as well as
early‐onset preeclampsia.
To conclude, SSRI use in early and midpregnancy does not sub-
stantially increase the risk of late‐onset preeclampsia. This information
may assist clinicians when evaluating the risk of treatment with SSRIs
versus that of nonmedicated depression. The elevated risk of late‐
onset preeclampsia (mainly mild) among SSRI‐exposed in late preg-
nancy needs to be refuted or confirmed by additional studies with
greater numbers of exposed cases. Whether SNRIs and TCAs have
an etiological role in relation to early‐ and late‐onset preeclampsia
needs to be further elucidated in both epidemiological and biological
research.
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